|
aap Confirms Successful Turnaround with Consolidated Financial Statements for 2005 and Q1/2006 Sales Figures
2005: 16% Sales Growth, Net Profit for Year, EBITDA EUR 2.3 million
Q1/2006: 40% Sales Growth
aap Implantate AG, a medical technology company active in the fields of biomaterials and implants for trauma and joint reconstruction, has achieved its forecasts for fiscal 2005 by reporting sales growth of 16% to EUR 13.4 million (previous year: EUR 11.5 million) and a net profit for the year of EUR 655K (previous year: EUR minus 140K). Sales growth adjusted for acquisitions was up 14% to EUR 13.1 million.
In EUR million | 2005 | 2004 | Change on year | Sales revenues | 13.4 | 11.5 | +16% | EBITDA | 2.3 | 1.2 | +93% | EBIT/Operating result | 0.9 | -0.3 | n. a. | EBT | 1.1 | -1.3 | n. a. | Net profit for the year | 0.7 | -0.1 | n. a. | Equity (ratio) | 19.4 (77%) | 15.5 (76%) | +25% | Balance sheet total | 25.1 | 20.4 | +23% | Employees | 139 | 109 | +28% |
For fiscal 2005 the Group reported EUR 2.3 million in EBITDA (previous year: EUR 1.2 million). EBT was EUR 1.1 million, or well above the previous year’s EUR minus 1.3 million.
The Group’s operating result (EBIT) improved to EUR 855K (previous year: EUR minus 316K). On a balance sheet total of EUR 25.1 million (previous year: EUR 20.4 million) the equity ratio was 77% (previous year: 76%).
Preliminary figures show the aap Group to have achieved 40% year-on-year sales growth to EUR 4.4 million (previous year: EUR 3.1 million) in the first quarter of 2006. The first quarter was not affected by special factors. Adjusted for acquisition, organic sales growth was 35%.
On the basis of this highly promising start to the new financial year the Management Board plans for 2006 sales growth in excess of 25% and double-digit EBIT and EBT margins.
The consolidated financial statements of aap Implantate AG for 2005 are available in full at www.aap.de to download. Publication of the report for the first quarter of 2006 is scheduled for May 15, 2006.
For further information, please contact:
aap Implantate AG | | Lorenzweg 5 | | D-12099 Berlin | | X | | Oliver Bielenstein | Nanette Hüdepohl | | Director/CFO | Investor & Public Relations | Tel.: +49 30 750 19 - 140 | Tel.: +49 30 75019 - 133 | Fax: +49 30 750 19 - 290 | Fax: +49 30 75019 - 290 | | X | | WKN 506660, ISIN DE0005066609 | | Prime Standard/Regulated Market | | Traded at all German Stock Exchanges |
|
Print this page
